Humanized anti-CCR2 Antibody for the Therapy of MS and RA
Scientists of the University of Göttingen and of the University of Regensburg developed in collaboration a proprietary anti-CCR2 antibodies for the therapy of Multiple Sclerosis (MS) and potentially Rheumatoid Arthritis (RA).The lead candidate Doc-2 has been humanized in collaboration with the MRC Technologies. It targets the CCR2 receptor and modulates the autoimmune process through depletion of CCR2+ monocytes.
Further information: PDF
MBM ScienceBridge GmbH
Phone: (0551) 30724-151
Contact
Dr. Jens-Peter Horst
As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Combining robotics and ChatGPT
TUM professor uses ChatGPT for choreographies with flying robots. Prof. Angela Schoellig has proved that large language models can be used safely in robotics. ChatGPT develops choreographies for up to…
How the Immune System Learns from Harmless Particles
Our lungs are bombarded by all manner of different particles every single day. Whilst some are perfectly safe for us, others—known as pathogens—have the potential to make us ill. The…
Biomarkers identified for successful treatment of bone marrow tumours
CAR T cell therapy has proven effective in treating various haematological cancers. However, not all patients respond equally well to treatment. In a recent clinical study, researchers from the University…
